Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 17/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24983863 | 0.93 | ABCB1 (0.61) | ABCB1CYP3A4MAPK1STING1 | |
| SCHEMBL30141115 | 0.93 | ABCB1 (0.61) | ABCB1CYP3A4MAPK1STING1 | |
| SCHEMBL30350414 | 0.92 | ABCB1 (0.58) | ABCB1CYP3A4MAPK1STING1 | |
| SCHEMBL23202777 | 0.92 | ABCB1 (0.58) | ABCB1CYP3A4MAPK1STING1 | |
| SCHEMBL21588114 | 0.91 | ABCB1 (0.54) | ABCB1CYP3A4MAPK1STING1 | |
| SCHEMBL513123 | 0.90 | ABCB1 (0.52) | ABCB1CYP3A4MAPK1STING1 | |
| SCHEMBL30141015 | 0.90 | ABCB1 (0.52) | ABCB1CYP3A4MAPK1STING1 | |
| SCHEMBL24983403 | 0.90 | ABCB1 (0.52) | ABCB1CYP3A4MAPK1STING1 | |
| SCHEMBL30892442 | 0.90 | ABCB1 (0.52) | ABCB1CYP3A4MAPK1STING1 | |
| SCHEMBL513122 | 0.90 | ABCB1 (0.52) | ABCB1CYP3A4MAPK1STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643405-B2 | Compound for treatment or prevention of liver diseases | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2023-05-09 | — | — | US | disclosed |
| US-11643405-B2 | Compound for treatment or prevention of liver diseases | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2023-05-09 | — | — | US | disclosed |
| US-20210246126-A1 | COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2021-08-12 | — | — | US | disclosed |
| US-20210246126-A1 | COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2021-08-12 | — | — | US | disclosed |
| EP-3805216-A1 | COMPOUNDS FOR TREATMENT OR PREVENTION OF LIVER DISEASES | Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
| EP-3805216-A1 | COMPOUNDS FOR TREATMENT OR PREVENTION OF LIVER DISEASES | Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
| WO-2019233440-A1 | COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES | 江苏新元素医药科技有限公司 (CN) | 2019-12-12 | — | — | WO | disclosed |
| WO-2019233440-A1 | COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES | 江苏新元素医药科技有限公司 (CN) | 2019-12-12 | — | — | WO | disclosed |
| US-7122573-B2 | Analogs of green tea polyphenols as chemotherapeutic and chemopreventive agents | SRI INTERNATIONAL (US) | 2006-10-17 | — | — | US | disclosed |
| US-7109236-B2 | Analogs of green tea polyphenols as chemotherapeutic and chemopreventive agents | SRI INTERNATIONAL (US) | 2006-09-19 | — | — | US | disclosed |
| US-20040192723-A1 | Analogs of green tea polyphenols as chemotherapeutic and chemopreventive agents | SRI INTERNATIONAL | 2004-09-30 | — | — | US | disclosed |
| WO-2004052873-A9 | ANALOGS OF GREEN TEA POLYPHENOLS AS CHEMOTHERAPEUTIC AND CHEMOPREVENTIVE AGENTS | STANFORD RES INST INT (US) | 2004-08-12 | — | — | WO | disclosed |
| US-20040110790-A1 | Analogs of green tea polyphenols as chemotherapeutic and chemopreventive agents | SRI INTERNATIONAL | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246126-A1 | COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES | SLC10A1, GYS2, CPT1A | ABCB1 131/4885CYP3A4 187/4885MAPK1 2177/4885 |
| US-20040192723-A1 | Analogs of green tea polyphenols as chemotherapeutic and chemopreventive agents | TEAD4, TEAD3, TEAD1 | ABCB1 218/4885CYP3A4 121/4885MAPK1 1688/4885 |
| US-20040110790-A1 | Analogs of green tea polyphenols as chemotherapeutic and chemopreventive agents | TEAD4, TEAD3, TEAD1 | ABCB1 218/4885CYP3A4 121/4885MAPK1 1688/4885 |
| US-11643405-B2 | Compound for treatment or prevention of liver diseases | SLC10A1, GYS2, CPT1A | ABCB1 131/4885CYP3A4 187/4885MAPK1 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.